These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 34638713)

  • 1. Cyclic GMP in Liver Cirrhosis-Role in Pathophysiology of Portal Hypertension and Therapeutic Implications.
    Kreisel W; Lazaro A; Trebicka J; Grosse Perdekamp M; Schmitt-Graeff A; Deibert P
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension.
    Schaffner D; Lazaro A; Deibert P; Hasselblatt P; Stoll P; Fauth L; Baumstark MW; Merfort I; Schmitt-Graeff A; Kreisel W
    World J Gastroenterol; 2018 Oct; 24(38):4356-4368. PubMed ID: 30344420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension.
    Kreisel W; Schaffner D; Lazaro A; Trebicka J; Merfort I; Schmitt-Graeff A; Deibert P
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32872119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure.
    Triposkiadis F; Xanthopoulos A; Skoularigis J; Starling RC
    Heart Fail Rev; 2022 Nov; 27(6):1991-2003. PubMed ID: 35437713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute-on-chronic liver disease enhances phenylephrine-induced endothelial nitric oxide release in rat mesenteric resistance arteries through enhanced PKA, PI3K/AKT and cGMP signalling pathways.
    Caracuel L; Sastre E; Llévenes P; Prieto I; Funes T; Aller MÁ; Arias J; Balfagón G; Blanco-Rivero J
    Sci Rep; 2019 May; 9(1):6993. PubMed ID: 31061522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats.
    Brusilovskaya K; Königshofer P; Lampach D; Szodl A; Supper P; Bauer D; Beer A; Stift J; Timelthaler G; Oberhuber G; Podesser BK; Seif M; Zinober K; Rohr-Udilova N; Trauner M; Reiberger T; Schwabl P
    United European Gastroenterol J; 2020 Dec; 8(10):1174-1185. PubMed ID: 32878579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of vascular nitric oxide production and systemic hemodynamics in cirrhosis versus prehepatic portal hypertension in rats.
    Niederberger M; Ginés P; Martin PY; Tsai P; Morris K; McMurtry I; Schrier RW
    Hepatology; 1996 Oct; 24(4):947-51. PubMed ID: 8855203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The nitric oxide-soluble guanylate cyclase-cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase.
    Benza RL; Grünig E; Sandner P; Stasch JP; Simonneau G
    Eur Respir Rev; 2024 Jan; 33(171):. PubMed ID: 38508664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homogeneous single-label cGMP detection platform for the functional study of nitric oxide-sensitive (soluble) guanylyl cyclases and cGMP-specific phosphodiesterases.
    Kopra K; Sharina I; Martin E; Härmä H
    Sci Rep; 2020 Oct; 10(1):17469. PubMed ID: 33060787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombin has biphasic effects on the nitric oxide-cGMP pathway in endothelial cells and contributes to experimental pulmonary hypertension.
    Nickel KF; Laux V; Heumann R; von Degenfeld G
    PLoS One; 2013; 8(6):e63504. PubMed ID: 23785394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble Guanylyl Cyclase Activator BI 685509 Reduces Portal Hypertension and Portosystemic Shunting in a Rat Thioacetamide-Induced Cirrhosis Model.
    Jones AK; Chen H; Ng KJ; Villalona J; McHugh M; Zeveleva S; Wilks J; Brilisauer K; Bretschneider T; Qian HS; Fryer RM
    J Pharmacol Exp Ther; 2023 Jul; 386(1):70-79. PubMed ID: 37230799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the BDL rat model.
    Hu L; Su L; Dong Z; Wu Y; Lv Y; George J; Wang J
    J Mol Med (Berl); 2019 Mar; 97(3):423-434. PubMed ID: 30721324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoregulation of nitric oxide-soluble guanylate cyclase-cyclic GMP signalling in mouse thoracic aorta.
    Hussain MB; Hobbs AJ; MacAllister RJ
    Br J Pharmacol; 1999 Nov; 128(5):1082-8. PubMed ID: 10556946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble Guanylate Cyclase Stimulators and Activators: Where are We and Where to Go?
    Xiao S; Li Q; Hu L; Yu Z; Yang J; Chang Q; Chen Z; Hu G
    Mini Rev Med Chem; 2019; 19(18):1544-1557. PubMed ID: 31362687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired effect of salt loading on nitric oxide-mediated relaxation in aortas from stroke-prone spontaneously hypertensive rats.
    Kagota S; Kubota Y; Nejime N; Nakamura K; Kunitomo M; Shinozuka K
    Clin Exp Pharmacol Physiol; 2007; 34(1-2):48-54. PubMed ID: 17201735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel peptide for attenuation of hypoxia-induced pulmonary hypertension via modulation of nitric oxide release and phosphodiesterase -5 activity.
    Hu H; Zharikov S; Patel JM
    Peptides; 2012 May; 35(1):78-85. PubMed ID: 22465621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-day tetrahydrobiopterin therapy increases in vivo hepatic NOS activity and reduces portal pressure in CCl4 cirrhotic rats.
    Matei V; Rodríguez-Vilarrupla A; Deulofeu R; García-Calderó H; Fernández M; Bosch J; Garcia-Pagán JC
    J Hepatol; 2008 Aug; 49(2):192-7. PubMed ID: 18534709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NO signaling through cGMP in renal tissue fibrosis and beyond: key pathway and novel therapeutic target.
    Wang-Rosenke Y; Neumayer HH; Peters H
    Curr Med Chem; 2008; 15(14):1396-406. PubMed ID: 18537617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Endothelium-Dependent Nitric Oxide-cGMP Pathway.
    Mónica FZ; Bian K; Murad F
    Adv Pharmacol; 2016; 77():1-27. PubMed ID: 27451093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats.
    Trebicka J; Leifeld L; Hennenberg M; Biecker E; Eckhardt A; Fischer N; Pröbsting AS; Clemens C; Lammert F; Sauerbruch T; Heller J
    Hepatology; 2008 Apr; 47(4):1264-76. PubMed ID: 18318439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.